These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 20629520)

  • 1. Successful management of pregnancy occurring in a patient with chronic myeloid leukemia on dasatinib.
    Kroll T; Ames MB; Pruett JA; Fenske TS
    Leuk Lymphoma; 2010 Sep; 51(9):1751-3. PubMed ID: 20629520
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment using low-dose dasatinib for chronic myelogenous leukemia in a patient with megakaryoblastic transformation concomitant with myelofibrosis and an extramedullary tumor.
    Yamaguchi M; Munemoto S; Kasada A; Murata R; Ueda M
    Leuk Res; 2010 Sep; 34(9):e237-9. PubMed ID: 20371117
    [No Abstract]   [Full Text] [Related]  

  • 3. Favorable conception and pregnancy involving a male patient affected by chronic myeloid leukemia while taking dasatinib.
    Gentile M; Guido M; Lucia E; Vigna E; Mazzone C; Recchia AG; Morabito F
    Leuk Lymphoma; 2014 Mar; 55(3):709-10. PubMed ID: 23741978
    [No Abstract]   [Full Text] [Related]  

  • 4. Systemic dasatinib fails to prevent development of central nervous system progression in a patient with BCR-ABL unmutated Philadelphia chromosome-positive leukemia.
    Frigeri F; Arcamone M; Luciano L; Di Francia R; Pane F; Pinto A
    Blood; 2009 May; 113(20):5028-9. PubMed ID: 19443672
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib.
    Oweini H; Otrock ZK; Mahfouz RA; Bazarbachi A
    Arch Gynecol Obstet; 2011 Jan; 283(1):133-4. PubMed ID: 20473616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pregnancy in patients with chronic myeloid leukemia treated with imatinib.
    Yilmaz M; Demirhan O; Kuçukosmanoglu E; Pehlivan M; Okan V; Balat O; Pehlivan S
    Leuk Lymphoma; 2007 Dec; 48(12):2454-6. PubMed ID: 18067024
    [No Abstract]   [Full Text] [Related]  

  • 7. Response to treatment in women with chronic myeloid leukemia during pregnancy and after delivery.
    Klamová H; Marková M; Moravcová J; Sisková M; Cetkovský P; Machová Poláková K
    Leuk Res; 2009 Nov; 33(11):1567-9. PubMed ID: 19580997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib.
    Cea M; Cirmena G; Garuti A; Rocco I; Palermo C; Cagnetta A; Moran E; Colombo N; Grasso R; Fugazza G; Gobbi M; Nencioni A; Ballestrero A; Patrone F
    Leuk Res; 2010 Sep; 34(9):e240-2. PubMed ID: 20447687
    [No Abstract]   [Full Text] [Related]  

  • 9. Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib.
    Valent JN; Schiffer CA
    Leuk Res; 2011 Jan; 35(1):e1-3. PubMed ID: 20888043
    [No Abstract]   [Full Text] [Related]  

  • 10. [Pharmacological properties and clinical efficacy of dasatinib hydrate (Sprycel), an anticancer drug for chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia].
    Fujii Y; Amano M; Seriu T
    Nihon Yakurigaku Zasshi; 2009 Sep; 134(3):159-67. PubMed ID: 19749489
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful pregnancy in a patient with chronic myeloid leukaemia exposed to dasatinib during the first trimester.
    Bayraktar S; Morency B; Escalón MP
    BMJ Case Rep; 2010 Oct; 2010():. PubMed ID: 22791487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence of molecular remission throughout pregnancy in CML after imatinib.
    Sorà F; De Matteis S; Bajer J; D'alò F; Leone G; Sica S
    Leuk Res; 2009 Jun; 33(6):e6-7. PubMed ID: 18937976
    [No Abstract]   [Full Text] [Related]  

  • 13. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia.
    Dumitrescu D; Seck C; ten Freyhaus H; Gerhardt F; Erdmann E; Rosenkranz S
    Eur Respir J; 2011 Jul; 38(1):218-20. PubMed ID: 21719499
    [No Abstract]   [Full Text] [Related]  

  • 14. Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities.
    Valent P
    Haematologica; 2011 Oct; 96(10):1395-7. PubMed ID: 21972208
    [No Abstract]   [Full Text] [Related]  

  • 15. [New horizon of chronic myelogenous leukemia].
    Tauchi T; Ohyashiki K
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():617-21. PubMed ID: 17474470
    [No Abstract]   [Full Text] [Related]  

  • 16. Are SRC family kinases responsible for imatinib- and dasatinib-resistant chronic myeloid leukemias?
    Chen Y
    Leuk Res; 2011 Jan; 35(1):27-9. PubMed ID: 20723974
    [No Abstract]   [Full Text] [Related]  

  • 17. Dasatinib-induced response in a rare case of chronic lymphocytic leukaemia associated with chronic myeloid leukaemia.
    Tecchio C; Nichele I; Todeschini G; Pizzolo G; Ambrosetti A
    Br J Haematol; 2009 Jul; 146(2):222-3. PubMed ID: 19466973
    [No Abstract]   [Full Text] [Related]  

  • 18. A once-daily dasatinib dosing strategy for chronic myeloid leukemia.
    Bryant G
    Clin J Oncol Nurs; 2009 Jun; 13(3):316-23. PubMed ID: 19502190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dasatinib in chronic myelogenous leukemia.
    Chu SC; Tang JL; Li CC
    N Engl J Med; 2006 Sep; 355(10):1062-3; author reply 1063-4. PubMed ID: 16960978
    [No Abstract]   [Full Text] [Related]  

  • 20. Multitargeted sequential therapy with MK-0457 and dasatinib followed by stem cell transplantation for T315I mutated chronic myeloid leukemia.
    Sanchez-Guijo FM; Lopez-Jimenez J; Gonzalez T; Santamaría C; González M; Del Cañizo MC
    Leuk Res; 2009 Jun; 33(6):e20-2. PubMed ID: 19038446
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.